ACE2 and COVID-19: This variant was not previously reported in relation to COVID-19; however, IL4 has been studied regarding susceptibility to SARS-CoV infection, and it was found that its protein product downregulates cell surface expression of ACE2, therefore inhibiting SARS-CoV replication (de Lang et al., 2006).